Johnson & Johnson Stock Forecast for 2023 - 2025 - 2030
Updated on 06/09/2023
Johnson & Johnson Stock Forecast and Price Target
Johnson & Johnson's most recent price target of $180.50 for 2023 was provided by six renowned analysts over the past few months, with an average prediction of $180.50. If this prediction is correct, Johnson & Johnson's stock could rise by 12.63 percent from its current trading price. The potential increase for the stock is $180.50 per share, with a possible range of $164.00 to $215.00. Even if you are not interested in JNJ stock, you should still be aware of its competitors.
12.63% Upside
Johnson & Johnson Fair Value Forecast for 2023 - 2025 - 2030
Johnson & Johnson's Price has decreased In the last four years, from $145.28 to $121.83 – a 16.14% drop. In the next year, analysts predict that Fair Value will reach $193.94 – an increase of 59.18%. For the next eight years, the forecast is for Fair Value to grow by 89.50%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly & Co | Outperform |
14
|
$445.62 | $333.19 | -10.24% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$39.09 | $47.96 | 34.69% |
| MRK Stock Forecast | Merck | Outperform |
5
|
$110.32 | $99.57 | 6.96% |
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$65.30 | $80.99 | 27.11% |
| REGN Stock Forecast | Regeneron Pharmaceuticals Inc | Outperform |
2
|
$750.12 | $796.73 | 4.25% |
Johnson & Johnson Revenue Forecast for 2023 - 2025 - 2030
Johnson & Johnson's Revenue has grown in the last four years, jumping from $81.58B to $94.94B – an increase of 16.38%. In the next year, analysts predict that Revenue will reach $100.28B – an increase of 5.62%. For the next eight years, the forecast is for Revenue to grow by 10.90%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
13
|
$332.50 | $363.29 | -1.95% |
| ZTS Stock Forecast | Zoetis | Outperform |
18
|
$164.26 | $209.70 | 24.80% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$41.34 | $60.73 | 40.30% |
Johnson & Johnson Dividend per Share Forecast for 2023 - 2025 - 2030
In the last four years, Johnson & Johnson's Dividend per Share has increased by 27.68%, going from $3.54 to $4.52. In the next year, analysts are expecting an increase in Dividend per Share, predicting it will reach $4.63 – an increase of 2.43%. The Johnson & Johnson forecast is for Dividend per Share to reach $5.75 or grow by 27.21%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$190.43 | $244.18 | 31.81% |
| VTRS Stock Forecast | Viatris | Outperform |
8
|
$9.53 | $13.70 | 41.66% |
| UTHR Stock Forecast | United Therapeutics | Outperform |
12
|
$226.50 | $280.69 | 30.24% |
Johnson & Johnson Free Cash Flow Forecast for 2023 - 2025 - 2030
Johnson & Johnson's Free Cash Flow has increased by 104025566.98% In the last four years, going from $18.53B to $19277.00T. According to 7 analysts, Johnson & Johnson's Free Cash Flow will fall by 100.00% in the next year, reaching $26.97B. Professionals believe that By 2030, Johnson & Johnson's Free Cash Flow will fall to $29.17B – a 100.00% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| CTLT Stock Forecast | Catalent | Outperform |
15
|
$39.00 | $83.92 | 87.18% |
| IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$41.65 | $52.42 | 20.05% |
| CYTK Stock Forecast | Cytokinetics | Outperform |
10
|
$38.06 | $62.67 | 57.65% |
Johnson & Johnson Net Income Forecast for 2023 - 2025 - 2030
In the last four years, Johnson & Johnson's Net Income has grown, increasing from $15.30B to $17.94B – an increase of 17.28%. For next year, the 17 analysts predict Net Income of $28.77B, which would mean an increase of 60.37%. Over the next eight years, the pros' prediction is Net Incomeof $29.27B, which would mean a eight-year growth forecast of 63.15%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$134.53 | $163.67 | 21.91% |
| NEOG Stock Forecast | Neogen | Hold |
16
|
$18.86 | $37.00 | 35.21% |
| CORT Stock Forecast | Corcept Therapeutics | Outperform |
16
|
$24.04 | $0.00 | 22.71% |
Johnson & Johnson EBITDA Forecast for 2023 - 2025 - 2030
In the last four years, Johnson & Johnson's EBITDA has decreased from $28.10B to $24.02B – a 14.52% drop. The next year looks promising for Johnson & Johnson, with analysts predicting EBITDA of $36.70B – an increase of 52.76%. Over the next eight years, experts anticipate that Johnson & Johnson's EBITDA will grow at a rate of 46.52%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$28.98 | $73.38 | -34.44% |
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£165.30 | £3.79 | -97.13% |
| PCRX Stock Forecast | Pacira BioSciences | Outperform |
16
|
$37.01 | $79.67 | 110.75% |
Johnson & Johnson EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Johnson & Johnson's EBIT has grown by 19.23%, from $21.18B to $25.25B. For the next year, analysts are expecting EBIT to reach $33.15B – an increase of 31.29%. Over the next eight years, experts predict that EBIT will grow by 68.35%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$45.89 | $41.00 | -4.12% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Hold |
14
|
$11.60 | $12.60 | 7.76% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$35.59 | $35.50 | -4.47% |
Johnson & Johnson EPS Price Prediction Forecast for 2023 - 2025 - 2030
Johnson & Johnson's EPS has decreased In the last four years, from $8.18 to $6.86 – a 16.14% drop. In the next year, analysts predict that EPS will reach $10.92 – an increase of 59.18%. For the next eight years, the forecast is for EPS to grow by 89.50%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| LGND Stock Forecast | Ligand Pharmaceuticals | Outperform |
14
|
$72.13 | $195.43 | 119.74% |
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$269.20 | $170.08 | -34.99% |
| USNA Stock Forecast | USANA Health Sciences | Hold |
14
|
$63.68 | $104.00 | -10.49% |